Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07661420 · ClinicalTrials.gov registry record · Phase 1
211At-MABG in Adults With Advanced Neuroendocrine Cancers
A Phase 1 study, sponsored by University of Pennsylvania.
- Not yet
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07661420: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT07661420 is a Phase 1 study that has not yet begun recruiting, run by University of Pennsylvania. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07661420, a Phase 1 study, has not yet begun recruiting, sponsored by University of Pennsylvania.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).
Interventions
- DRUG 1 MBq/k of 211At-MABG Fractionated
- DRUG 2 MBq/k1 of 211At-MABG Fractionated
- DRUG 4 MBq/k of 211At-MABG Fractionated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2032-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07661420
The ClinicalTrials.gov registry entry for NCT07661420 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 1 MBq/k of 211At-MABG Fractionated is the first listed.
NCT07661420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07661420 about?
NCT07661420 is a clinical study titled "211At-MABG in Adults With Advanced Neuroendocrine Cancers". Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standar...
What is the current status of trial NCT07661420?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-08-01. Estimated completion is 2032-08-01.
What interventions are being tested in trial NCT07661420?
The interventions under investigation include: 1 MBq/k of 211At-MABG Fractionated (DRUG), 2 MBq/k1 of 211At-MABG Fractionated (DRUG), 4 MBq/k of 211At-MABG Fractionated (DRUG).
Who is sponsoring clinical trial NCT07661420?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.